Loading...
Loading...
GENMAB A/S
GENMAB A/S. Spoken Alpha tracks GNMSF's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks GNMSF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for GNMSF.
curl https://api.spokenalpha.com/v1/companies/GNMSF| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.75 | $1.39 | +26.0% | +1.5% | -0.9% |
| Q4 FY2026 | $1.86 | $1.42 | +31.3% | +2.0% | +1.1% |
| Q3 FY2026 | $1.60 | $1.29 | +23.9% | -5.1% | -2.3% |
| Q2 FY2026 | $1.87 | $1.37 | +36.3% | +0.4% | +2.3% |
| Q1 FY2025 | $2.16 | $1.59 | +35.8% | +0.1% | +2.1% |
| Q4 FY2025 | $1.81 | $1.43 | +26.6% | +5.4% | +5.8% |
| Q3 FY2025 | $1.82 | $1.49 | +22.2% | -1.6% | -0.9% |
| Q2 FY2025 | $2.03 | $1.57 | +29.3% | -5.1% | -7.0% |
| Q1 FY2024 | $1.87 | $1.43 | +31.0% | -3.7% | -3.4% |
| Q4 FY2024 | $1.99 | $1.63 | +22.3% | -4.8% | -1.8% |